{"id":"W4410945979","doi":"10.1016/j.ygyno.2025.04.578","title":"OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":11,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Daiichi Sankyo Europe; Natera; Seagen; Eisai; BeiGene; National Institutes of Health; Novocure; AstraZeneca; Pfizer; Imunon","keywords":"Medicine; Debulking; Internal medicine; Carboplatin; Clinical endpoint; Chemotherapy; Ovarian cancer; Adjuvant; Gastroenterology; Randomized controlled trial; Urology; Oncology; Phases of clinical research; Surgery; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002220455,0.001598287,0.001971014,0.000461376,0.0003316973,0.0008217377,0.0008058693,0.001475452,0.003857067],"category_scores_gemma":[0.001181361,0.0007253434,0.00111367,0.0003524359,0.001344493,0.000968403,0.0003661833,0.00245013,0.0005613762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007530726,"about_ca_system_score_gemma":0.001348785,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005158035,"about_ca_topic_score_gemma":0.001315183,"domain_scores_codex":[0.9994351,0.00032646,0.00002705252,0.00008837444,0.00004979845,0.00007318831],"domain_scores_gemma":[0.9990575,0.0002067563,0.0002537158,0.00008618706,0.000051713,0.0003442032],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9335294,0.03423186,0.001951382,0.0004088726,0.0004571224,0.00005875299,0.00005491695,0.0004732625,0.01252356,0.0001035638,0.0005380596,0.01566911],"study_design_scores_gemma":[0.8134215,0.1823366,0.001740247,0.00001103524,0.0002042811,0.00004324801,0.00001079371,0.0003588405,0.001306186,0.00004728577,0.000510919,0.000009007287],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930165,0.001154016,0.000472489,0.0002758755,0.0001624888,0.003539149,0.0005085244,0.00006550861,0.0008054751],"genre_scores_gemma":[0.9859162,0.001329743,0.001930392,0.00077363,0.000366308,0.005708782,0.001129383,0.00002848144,0.00281699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003857067,"threshold_uncertainty_score":0.01290321,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0141862198773747,"score_gpt":0.3188930408041692,"score_spread":0.3047068209267945,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}